Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

BASF Will Manufacture Astaxanthin for Cardax

  • BASF will exclusively manufacture a specialized form of astaxanthin, a key intermediate used to make Cardax Pharmaceuticals’ lead compound, Xancor™, for cardiovascular inflammatory disease.

    BASF will produce this material in sufficient quantity for preclinical, clinical, and eventually commercial use, according to the joint development and supply agreement between the two companies.

    As part of the agreement, Cardax has granted BASF an option for a royalty-bearing license for nutraceutical use of the specialized form of astaxanthin. All pharmaceutical applications of Xancor will remain the property of Cardax.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »